Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Sep;8(3):111-119.
doi: 10.1007/s40135-020-00235-z. Epub 2020 Jun 4.

Effect of Intravitreal Injections on Retinal Imaging Metrics in Glaucomatous and Non-Glaucomatous Eyes

Ronaldo Nuesi  1   2 , Swarup S Swaminathan  1
Affiliations

Effect of Intravitreal Injections on Retinal Imaging Metrics in Glaucomatous and Non-Glaucomatous Eyes

Ronaldo Nuesi et al. Curr Ophthalmol Rep. 2020 Sep.

Abstract

Purpose of review: To summarize the available literature on retinal imaging metrics in the context of intravitreal injections in glaucomatous and non-glaucomatous eyes.

Recent findings: The retinal nerve fiber layer (RNFL) in injected non-glaucomatous eyes appears to thin at a similar rate to uninjected fellow eyes. A total of four studies evaluating RNFL thinning in injected glaucomatous eyes yielded mixed results, with more recent longitudinal investigations suggesting a potential association. The ganglion cell-inner plexiform layer is also being studied as a potential endpoint in both glaucomatous and non-glaucomatous eyes following intravitreal injections.

Keywords: Ganglion cell layer; Ganglion cell-inner plexiform layer; Glaucoma; Intravitreal injections; Ocular hypertension; Optic nerve; Retinal nerve fiber layer.

PubMed Disclaimer

Conflict of interest statement

Compliance with Ethical Standards Conflicts of Interest The authors declare that they have no conflict of interest.

Similar articles

See all similar articles

Cited by

References

    1. Quigley HA. Glaucoma. Lancet (London, England). 2011;377(9774):1367–77. doi:10.1016/s0140-6736(10)61423-7. - DOI - PubMed
    1. Klein R, Klein BE. The prevalence of age-related eye diseases and visual impairment in aging: current estimates. Investigative ophthalmology & visual science. 2013;54(14):Orsf5-orsf13. doi:10.1167/iovs.13-12789. - DOI - PMC - PubMed
    1. Bourne RRA, Jonas JB, Flaxman SR, Keeffe J, Leasher J, Naidoo K et al. Prevalence and causes of vision loss in high-income countries and in Eastern and Central Europe: 1990–2010. British Journal of Ophthalmology. 2014;98(5):629–38. doi:10.1136/bjophthalmol-2013-304033. - DOI - PubMed
    1. Grzybowski A, Told R, Sacu S, Bandello F, Moisseiev E, Loewenstein A et al. 2018 Update on Intravitreal Injections: Euretina Expert Consensus Recommendations. Ophthalmologica Journal international d’ophtalmologie International journal of ophthalmology Zeitschrift fur Augenheilkunde. 2018;239(4):181–93. doi:10.1159/000486145. - DOI - PubMed
    1. Hoguet A, Chen PP, Junk AK, Mruthyunjaya P, Nouri-Mahdavi K, Radhakrishnan S et al. The Effect of Anti-Vascular Endothelial Growth Factor Agents on Intraocular Pressure and Glaucoma: A Report by the American Academy of Ophthalmology. Ophthalmology. 2019;126(4):611–22. doi:10.1016/j.ophtha.2018.11.019. - DOI - PubMed

LinkOut - more resources